Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
The latest announcement is out from HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ).
Hemogenyx Pharmaceuticals has announced a strategic collaboration with Kure.ai to develop an ultrafast CAR-T manufacturing process aimed at treating acute myeloid leukemia (AML) and a subset of acute lymphoblastic leukemia (ALL). This partnership seeks to integrate Kure’s advanced manufacturing technology with Hemogenyx’s proprietary CAR-T therapy, HG-CT-1, to significantly shorten production times while maintaining therapeutic efficacy. This initiative is expected to enhance Hemogenyx’s position in the biopharmaceutical industry by potentially revolutionizing CAR-T therapy production, which could accelerate patient access to life-saving treatments. The collaboration includes a clinical study, process development, and the option for Hemogenyx to license Kure’s technology, which could have substantial implications for stakeholders and patients by improving treatment timelines and outcomes for AML, a disease with notably poor survival rates.
More about HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals is a clinical stage biopharmaceutical company publicly traded on the London Stock Exchange (LSE: HEMO), with operations in both London and New York City. The company focuses on developing innovative therapies for blood and autoimmune diseases, aiming to expand the use of bone marrow transplantation to treat life-threatening conditions. Hemogenyx Pharmaceuticals is advancing several product candidates and utilizes a platform technology for novel product development.
YTD Price Performance: -61.96%
Average Trading Volume: 34,959
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £12.27M
Find detailed analytics on HEMO stock on TipRanks’ Stock Analysis page.